2. Others
  3. Others
  4. SRI-37330

SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research.

For research use only. We do not sell to patients.

SRI-37330 Chemical Structure

SRI-37330 Chemical Structure

CAS No. : 2322245-42-9

Size Price Stock Quantity
1 mg USD 36 In-stock
5 mg USD 120 In-stock
10 mg USD 190 In-stock
25 mg USD 450 In-stock
50 mg USD 780 In-stock
100 mg USD 1250 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of SRI-37330:

SRI-37330 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research[1].

IC50 & Target

TXNIP[1]
In Vitro

SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells[1].
SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells[1].
SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter[1].
SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells[1].
SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SRI-37330 Related Antibodies

RT-PCR[1]

Cell Line: INS-1 cells
Concentration: 1 μM
Incubation Time: 24 h
Result: Inhibited endogenous TXNIP mRNA expression with an IC50 of 0.64 μM.
In Vivo

SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice[1].
SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J mice[1]
Dosage: 100 mg/kg
Administration: Oral administration (p.o.), in drinking water, 3 weeks.
Result: Lowered serum glucagon levels, inhibited hepatic glucose production and improved glucose homeostasis in mice.
Molecular Weight

388.41

Formula

C16H19F3N4O2S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CS(=O)(NCC1CN(C2=C3C=C(C(F)(F)F)C=CC3=NC=N2)CCC1)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (257.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5746 mL 12.8730 mL 25.7460 mL
5 mM 0.5149 mL 2.5746 mL 5.1492 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (12.87 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 5 mg/mL (12.87 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5746 mL 12.8730 mL 25.7460 mL 64.3650 mL
5 mM 0.5149 mL 2.5746 mL 5.1492 mL 12.8730 mL
10 mM 0.2575 mL 1.2873 mL 2.5746 mL 6.4365 mL
15 mM 0.1716 mL 0.8582 mL 1.7164 mL 4.2910 mL
20 mM 0.1287 mL 0.6436 mL 1.2873 mL 3.2182 mL
25 mM 0.1030 mL 0.5149 mL 1.0298 mL 2.5746 mL
30 mM 0.0858 mL 0.4291 mL 0.8582 mL 2.1455 mL
40 mM 0.0644 mL 0.3218 mL 0.6436 mL 1.6091 mL
50 mM 0.0515 mL 0.2575 mL 0.5149 mL 1.2873 mL
60 mM 0.0429 mL 0.2145 mL 0.4291 mL 1.0727 mL
80 mM 0.0322 mL 0.1609 mL 0.3218 mL 0.8046 mL
100 mM 0.0257 mL 0.1287 mL 0.2575 mL 0.6436 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SRI-37330 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SRI-373302322245-42-9SRI37330SRI 37330OthersINS-1 cellTXNIPobesitySTZdiabetessteatosisglucagon secretionhepatocytesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SRI-37330
Cat. No.:
HY-142114
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.